eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
6/2023
vol. 15
 
Share:
Send email
Share:
abstract:
Original paper

Hydrogel spacer injection to the meso-sigmoid to protect the sigmoid colon in cervical cancer brachytherapy: A technical report

Madoka Sakuramachi
1
,
Naoya Murakami
1, 2
,
Ayaka Nagao
1
,
Kanako Kojima
2
,
Yusaku Miyata
3
,
Tairo Kashihara
1
,
Tomoya Kaneda
1
,
Kana Takahashi
1
,
Koji Inaba
1
,
Kae Okuma
1
,
Yuko Nakayama
1
,
Hiroyuki Okamoto
4
,
Mitsuya Ishikawa
5
,
Hiroshi Igaki
1

  1. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
  2. Department of Radiation Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan
  3. Department of Radiology, Kurume University School of Medicine, Fukuoka, Japan
  4. Radiation Safety and Quality Assurance Division, National Cancer Center Hospital, Tokyo, Japan
  5. Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
J Contemp Brachytherapy 2023; 15, 6: 465–469
DOI: https://doi.org/10.5114/jcb.2023.134174
Online publish date: 2023/12/29
View full text Get citation
 
Purpose:
The use of a hydrogel spacer inserted into recto-vaginal fossa is a valuable strategy to mitigate radiation exposure to the rectum during radiation therapy for female pelvic malignancies. However, when the sigmoid colon is in proximity to the cervix, radiation exposure to the sigmoid colon cannot be adequately mitigated with a hydrogel spacer injected into the recto-vaginal fossa. Here, we presented a case, in which a hydrogel spacer was injected into the meso-sigmoid to protect the sigmoid colon.

Material and methods:
A 73-year-old female diagnosed with T3b stage IIIC2r uterine cervical cancer (FIGO 2018) underwent high-dose-rate interstitial brachytherapy consisting of 24 Gy in 4 fractions, following concurrent chemoradiotherapy with external beam radiation therapy of 50 Gy in 25 fractions of whole pelvic radiation therapy. In the initial brachytherapy, the sigmoid colon was in close contact with the uterine cervix. In the second brachytherapy, attempts to create a space between the sigmoid colon and uterine cervix using injected artificial ascites were unsuccessful due to rapid absorption of fluid. In the third and fourth brachytherapy fractions, 5 mL of hydrogel was injected into the meso-sigmoid through a pouch of Douglas under trans-rectal ultrasonography guidance. Dose ratio of sigmoid colon D2cc and high-risk clinical target volume (HR-CTV) D90 of each brachytherapy were evaluated.

Results:
Dose ratio of the sigmoid colon D2cc to HR-CTV D90 was 1.03, 0.43, 0.56, and 0.47 in each respective brachytherapy session, indicating dose escalation to HR-CTV whilst achieving acceptable sigmoid dose with hydrogel spacer injected into the meso-sigmoid.

Conclusions:
The dose ratio of the sigmoid colon to HR-CTV D90 was decreased by introducing a hydrogel spacer into the meso-sigmoid. In cases where the sigmoid colon is in proximity to the cervical tumor, this novel technique can be considered to achieve better clinical outcomes.

keywords:

brachytherapy, spacer, hydrogel spacer, gynecologic brachytherapy, sigmoid colon protection

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.